What are the leading stocks in biopharmaceutical stocks in 2023?
What are the sector leaders of biopharmaceutical stocks? Let’s take a look. First, let’s take a look at the leading stocks in the biopharmaceutical sector: Hengrui Pharmaceuticals, Mindray Medical, WuXi AppTec, Changchun High-tech, Zhifei Biotech, Hualan Biotech, Fosun Pharma, and Aier Ophthalmology. Below, the editor will bring you the leading stocks in the biopharmaceutical stocks sector in 2023. Let’s take a look together. I hope it can bring reference.
What are the leading stocks in the biopharmaceutical stocks sector?
1. Hengrui Pharmaceutical (600276), the first domestic innovative drug stock. The main product lines include anti-tumor, anesthesia, contrast agents, etc. The company's net return on assets has remained above 23% for many years, and its net profit has maintained a growth rate of more than 20% for many years. The company's R&D capabilities are very strong, its management team is excellent, and its sales capabilities are also strong. 2. Aier Eye Hospital (300015), the No. 1 ophthalmology hospital chain in China. It mainly provides patients with ophthalmic medical services such as diagnosis and treatment of various eye diseases
as well as medical optometry and glasses. The company's return on net assets has remained around 20% for many years, and its net profit has maintained a growth rate of over 30%
for many years. The company's business model is relatively excellent, and its operating capabilities and brand reputation continue to increase. 3. Mindray Medical (300760), the first domestic medical device stock. The main product lines include life and information support, in vitro diagnostics, medical imaging, etc. The company's return on net assets has remained above 25% for many years, and its net profit has maintained a growth rate of more than 25% for many years. As a leader in medical devices that has completed its global layout, the company has steadily advanced in high-end and platform-based operations, with a very solid position and huge long-term space. 4. Changchun High-tech (000661), the first domestic biopharmaceutical stock. The main product lines include growth hormone, syncytial virus vaccine, etc. The company's return on net assets has remained above 16% for many years, and its net profit has maintained a growth rate of more than 30% for many years. As my country's leading biopharmaceutical company, the company's performance has exceeded expectations. 5. WuXi AppTec (603259), the first domestic medical R&D services company. The main business is the comprehensive and integrated platform services for the discovery, development and production of small molecule chemical drugs. The company's return on net assets has remained above 20% for many years, and its net profit has maintained a growth rate of 25% and above for many years. The company is the world's leading pharmaceutical R&D service platform with a vast market space and its performance is expected to maintain rapid growth. 6. Tigermed (300347), the leading clinical contract research organization (CRO) in China. The main business is to provide clinical research services such as phase I to phase IV clinical trial technical services and data management for pharmaceutical product research and development. The company's return on net assets has increased to around 17% in the past two years
and its net profit has maintained a growth rate of over 56% for many years. 7. Wowu Biology (300357), the first domestic desensitization diagnosis and treatment company. The company's dust mite drops have maintained rapid growth, and its blockbuster product Huanghua
Artemisia pollen sublingual drops has entered on-site inspection and is expected to be approved for marketing in 2020. The company's return on net assets has remained above 21% for many years, and its net profit has maintained a growth rate of more than 25% for many years. As the only leading sublingual desensitization company in my country, the company has an excellent competitive landscape
with a market share of over 80%. The company has great long-term growth potential. 8. Tongce Medical (600763), the first domestic dental chain. The company has launched a dental hospital chain layout through the "hospital replicable + doctor replicable + team replicable" model. The company's return on net assets has remained around 23% for many years, and its net profit has maintained a growth rate of around 50% for many years. my country's dental market has vast space, and the company is expected to achieve rapid development under the two major trends of population aging and consumption upgrading. 9. Antu Biotech (603658), the leading domestic IVD stock. The company is mainly engaged in the research and development, production and sales of in vitro diagnostic reagents and supporting instruments. The company's return on net assets has remained around 30% for many years, and its net profit has maintained a growth rate of more than 25% for many years. The chemiluminescence industry will enter an era of differentiation. With the advantages of 70% biological raw material assets, mainstream projects, and assembly lines, the company is expected to continue to replace foreign-funded and other domestic-funded products and maintain sustained growth.
10. Hualan Biotechnology (002007), the leading domestic blood products stock. The company's main product lines are blood products and vaccine products. The company's return on net assets has remained around 19% for many years, and its net profit has maintained a growth rate of around 30% for many years. As the domestic blood products industry slowly recovers and flu vaccines continue to increase in volume, the company's performance is expected to be further improved.
A list of leading biopharmaceutical stocks
On March 21, three pharmaceutical companies with a market value of over 100 billion announced their 2022 annual reports. Among them, WuXi AppTec’s revenue reached a record high last year, and its net profit increased by 70%; Wantai Biologics, which specializes in vaccines and in vitro diagnostics, nearly doubled its revenue, and its net profit increased by more than 130%; another vaccine company, Zhifei Biologics Net profit fell 26% year-on-year.
Financial Investment News
According to WIND statistics, 19 companies in the Shenwan pharmaceutical and biological industry have published annual reports, of which 16 have seen a year-on-year increase in net profit. Perhaps supported by strong performance, the pharmaceutical sector surged on March 21, with WuXi AppTec's share price soaring 8.5%.
WuXi AppTec’s business hits record
WuXi AppTec’s annual report in the pharmaceutical R&D services industry shows that in 2022, the company achieved operating income of 39.355 billion yuan, setting another record, with a year-on-year increase of 71.84% ; Net profit attributable to shareholders of the parent company was 8.814 billion yuan, a year-on-year increase of 72.91%.
In terms of business, WuXi AppTec’s chemical business, testing business, biology business, and cell and gene therapy CTDMO business have experienced growth, with revenue from the chemical business growing by more than 105%. Only the revenue of the domestic new drug research and development service department fell by 22.49% year-on-year, with revenue during the period of 970 million yuan.
Wuxi AppTec also saw significant growth in new customers last year. WuXi AppTec stated in its annual report that in 2022, the company will have more than 1,400 new customers and more than 5,950 active customers. The company's revenue from original customers was 37.781 billion yuan, a year-on-year increase of 77%; revenue from new customers was 1.573 billion yuan. Revenue from enterprises was 18.421 billion yuan, a year-on-year increase of 174%; revenue from other global customers was 20.934 billion yuan, a year-on-year increase of 30%.
At the same time, WuXi AppTec’s R&D expenses increased significantly by more than 70% last year, reaching 1.614 billion yuan, accounting for 4.1% of revenue. WuXi AppTec stated that the increase in R&D expenses was mainly due to the company's continued increase in R&D investment and further strengthening its service capabilities for new molecular types such as PROTACs, oligonucleotide drugs, peptide drugs, conjugate drugs, dual antibodies, cells and genes. .
The results of the two leading vaccines are in opposite directions
In addition to WuXi AppTec, two companies with a market value of 100 billion, Zhifei Biotech and Wantai Biotech, whose main products are vaccines, also announced their annual reports. .
Zhifei Biology’s annual report shows that in 2022, the company achieved operating income of 38.264 billion yuan, a year-on-year increase of 24.83%; net profit attributable to shareholders of the parent company was 7.539 billion yuan, a year-on-year decrease of 26.15%. Basic earnings per share were 4.711 yuan, a year-on-year decrease of 26.15%.
As for the reasons for the decline in performance, Zhifei Biotechnology believes that due to objective factors in 2022, the market demand and competition pattern of some of the company's products have undergone major changes, and their sales have dropped significantly compared with last year. However, with the improvement of public health awareness and willingness to be vaccinated, the market potential of non-immunization program vaccines has been continuously stimulated, and the market space has further expanded.
The research and development expenses of Zhifei Biotech in 2022 will be 854 million yuan, a year-on-year increase of 54.56%.
Zhifei Biotech’s main business is vaccine and biological product research and development, etc. Independent products include ACYW135 polysaccharide vaccine, AC conjugate vaccine, Hib vaccine and AC polysaccharide vaccine. Agent products include Merck’s quadrivalent HPV vaccine, nine-valent HPV vaccine, pentavalent rotavirus vaccine, 23-valent pneumonia vaccine and inactivated hepatitis A vaccine.
Wantai Biotech achieved revenue of 11.185 billion yuan last year, a year-on-year increase of 94.51%; net profit attributable to shareholders of listed companies was 4.736 billion yuan, a year-on-year increase of 134.27%; basic earnings per share was 5.31 yuan.
Wantai Biotech is mainly engaged in vaccines and in vitro diagnostics. Among them, both vaccines and in vitro diagnostics revenue increased, and the vaccine segment revenue increased by more than 152%.
The diagnostics division achieved a net profit of 817.6655 million yuan, accounting for 16.81%; the vaccine division achieved a net profit of 4.0456357 million yuan, accounting for 83.19%.
Wantai Biotech stated that the company’s bivalent cervical cancer vaccine continues to maintain strong production and sales, and its revenue and profits continue to maintain rapid growth. Its designed annual production capacity is 30 million units, with sales exceeding 25 million units. It has successively obtained marketing authorizations from four countries: Morocco, Nepal, Thailand, and the Democratic Republic of the Congo; the Phase III clinical trials of the nine-valent HPV vaccine are progressing smoothly.
Brokerages are optimistic about the comprehensive recovery of conventional medical demand
In addition to the above three leading pharmaceutical stocks, based on the Shenwan first-level industry classification, 16 other companies in the pharmaceutical and biological sector have announced annual report. Among a total of 19 companies, 16 companies achieved positive year-on-year net profit growth, with Wantai Biologics and WuXi AppTec leading the growth rate.
From the perspective of market performance, with the support of strong performance, the pharmaceutical sector rebounded strongly on March 21, with the Shenwan Pharmaceutical and Biological sector rising by 2.4%. rose 14.39% and 10%, while WuXi AppTec's stock price rose 8.46%, with a turnover of 4.4 billion yuan, and the stock price closed at 80.26 yuan. The share prices of Changchun High-tech, Jiuzhou Pharmaceutical, and Pharmaron Chemical all rose by more than 7%, and Wantai Biotech rose by more than 3.7%.
Capital Securities stated that with the end of policy suppression factors, the pharmaceutical industry has obvious "policy bottom" characteristics, and the valuation contraction has ended. At this stage, the pharmaceutical sector already has a high investment performance-price ratio, and once again ushered in allocation Good opportunity. From the perspective of operating trends, the impact of policies on the performance of pharmaceutical and medical device product companies, especially companies in the pharmaceutical industry, has gradually come to an end, and will soon enter a new profit growth cycle.
Shenwan Hongyuan expects that demand for routine medical care is expected to fully recover in 2023. ___ The medical section of the work report fully affirms the success of centralized purchasing and other cost control policies in reducing the medical burden in the past few years. At the same time, it was mentioned that in the future, we should promote the expansion and sinking of high-quality medical resources, strengthen the protection of elderly care services, and improve fertility support policies. It is expected that continued cost control will remain the main line of policy, and independent innovation, ethnic medicine, independent control of the industrial chain, AI+ medical care, and vitamin price increases are the current investment directions.
What are the leading pharmaceutical stocks?
Leading domestic generic drug stocks: Hengrui Pharmaceutical, Huadong Pharmaceutical, Huahai Pharmaceutical, Puli Pharmaceutical, Jingxin Pharmaceutical, and Xinlitai.
Tonghua Dongbao, the leader in second-generation insulin, Hualan Biotech, the leader in blood products, Kangtai Biotech, the leader in vaccines (this is controversial and needs to be subdivided into varieties), Fuhong Hanlin, the leader in monoclonal antibodies, etc. (monoclonal antibodies are relatively scattered , there are many companies with layout, including Hisun Biotech, Jiahe, etc.), growth hormone leader Changchun High-tech, and anti-allergic biopharmaceutical leader Wowu Biotech.
Baiyunshan 600332: Baiyunshan’s brand awareness and reputation have great influence and appeal among consumers across the country, and it is one of the most valuable pharmaceutical brands in China; Kunyao Group 600422: The annual profit of the pharmaceutical industry in 2015 is expected to be 260.2 billion yuan, a year-on-year increase of 19%, and the growth rate will decrease by 0.4 percentage points year-on-year.
The list of "leading pharmaceutical" stocks heavily held by foreign investors includes: Mindray Medical, Hengrui Pharmaceutical, Shanghai Pharmaceuticals, Baiyunshan, and Changchun High-tech.
What are the stocks in the pharmaceutical industry?
1. Pharmaceutical stocks include: Sinopharm, Shanghai Pharmaceuticals, Lukang Pharmaceutical, China Pharmaceutical, Wohua Pharmaceutical, etc. Wohua Medicine Wohua Medicine established Shandong Weifang Traditional Chinese Medicine Factory in January 1959 on the basis of the traditional Chinese medicine processing department of Wanhetang Pharmacy and the slice processing group of Shandong Changwei Central Medicinal Materials Company.
2. Domestic leading generic drug stocks: Hengrui Pharmaceutical, Huadong Pharmaceutical, Huahai Pharmaceutical, Puli Pharmaceutical, Jingxin Pharmaceutical, and Xinlitai.
3. The leading stocks of listed pharmaceutical companies include Tencent Holdings Co., Ltd., WuXi Biologics, and Sinopharm. Tencent Holdings Limited (00700.HK): Tencent Healthcare, a pharmaceutical subsidiary of Tencent, is one of China's leading Internet medical platforms and one of the leading companies in the pharmaceutical industry.
4. The leading pharmaceutical stocks include: Fuxiang Pharmaceutical (300497), Minova (603538), and Zixin Pharmaceutical (002118). The following is a detailed introduction to these stocks, interested investors can continue reading. Among them, Minova is one of the domestic companies that exports the most special APIs in Europe.